Unmet Needs in Patient Care for Metastatic Colorectal Cancer

Although trilaciclib appears to reduce neutropenia following treatment with FOLFOXIRI and bevacizumab in patients with metastatic colorectal cancer, the phase 3 PRESERVE 1 trial will be stopped due to a lack of responses.

Lead author Ibrahim Halil Sahin, MD, spoke with CancerNetwork® about his work investigating postoperative circulating tumor DNA dynamics in early-stage colon cancer as part of the CIRCULATE-US trial published in the journal ONCOLOGY®.

Findings from the phase 3 BREAKWATER study indicate that encorafenib plus cetuximab and chemotherapy produces activity and is well-tolerated in metastatic colorectal cancer harboring BRAF V600E mutations.

Tanios Bekaii-Saab, MD, talks with Kristen Ciombor, MD, MSCI, and John Strickler, MD, about targeted therapy resistance, rechallenge, and acquired resistance mutations in colorectal cancer.

Findings from the phase 3 SUNLIGHT study highlight favorable overall survival and disease control rates with the use of bevacizumab plus trifluridine and tipiracil in metastatic colorectal cancer.

Novel, personalized, tumor-informed brPROPHET technology can assess molecular residual disease with greater sensitivity than other assays, according to initial data.